Investors in the cancer-focused biotech had to stomach a 47% decline during the year, according to data from S&P Global Market Intelligence . That was a far worse decline than the 17% pullback that was rung up by the First Trust NYSE Arca Biotech ETF As the chart above indicates, Merrimack’s stock gave its investors a wild ride during 2016.